We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+199.34%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$404M
AUM Growth
+$265M
Cap. Flow
+$92M
Cap. Flow %
22.79%
Top 10 Hldgs %
66.28%
Holding
52
New
21
Increased
12
Reduced
5
Closed
14

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$11.7M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$8.58M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$7.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.11M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.05M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$6.16M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$5.49M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$5.03M
4
VCYT icon
Veracyte
VCYT
+$2.7M
5
ARGX icon
argenx
ARGX
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 83.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
26
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.43M 0.85%
+100,000
New +$1.2M
KURA icon
27
Kura Oncology
KURA
$816M
$3.3M 0.82%
240,000
+145,000
+153% +$2.15M
ZYME icon
28
Zymeworks
ZYME
$1.6B
$3.21M 0.79%
70,500
+18,000
+34% +$654K
IMMU
29
DELISTED
Immunomedics Inc
IMMU
$3.17M 0.79%
+150,000
New +$2.65M
ASND icon
30
Ascendis Pharma A/S
ASND
$16B
$3.13M 0.78%
+22,500
New +$2.5M
KALV
31
DELISTED
KalVista Pharmaceuticals
KALV
$1.92M 0.47%
107,500
+82,500
+330% +$1.08M
MDCO
32
DELISTED
Medicines Co
MDCO
$1.84M 0.46%
+21,700
New +$1.45M
QURE icon
33
uniQure
QURE
$3.06B
$1.79M 0.44%
+25,000
New +$1.37M
GRCE
34
Grace Therapeutics
GRCE
$33.8M
$1.52M 0.38%
+12,917
New +$1.28M
CCXI
35
DELISTED
ChemoCentryx, Inc.
CCXI
$1.38M 0.34%
+35,000
New +$615K
ADVM
36
CALL
DELISTED
Adverum Biotechnologies
ADVM
$1.15M 0.29%
+10,000
New +$881K
LRMR icon
37
Larimar Therapeutics
LRMR
$413M
$1.11M 0.27%
+83,333
New +$796K
XFOR icon
38
X4 Pharmaceuticals
XFOR
$386M
$428K 0.11%
+1,333
New +$478K
AMRN
39
Amarin Corp
AMRN
$297M
– –
-5,000
Closed -$1.52M
ARGX icon
40
argenx
ARGX
$52B
– –
-22,500
Closed -$2.56M
ASMB icon
41
Assembly Biosciences
ASMB
$503M
– –
-10,958
Closed -$1.29M
CRSP icon
42
CRISPR Therapeutics
CRSP
$4.88B
– –
-134,000
Closed -$5.49M
FOLD
43
DELISTED
Amicus Therapeutics
FOLD
– –
-140,000
Closed -$1.12M
IRIX icon
44
IRIDEX
IRIX
$14.4M
– –
-1,171,300
Closed -$2.17M
MRUS
45
DELISTED
Merus
MRUS
– –
-69,274
Closed -$1.23M
PTCT icon
46
PTC Therapeutics
PTCT
$5.68B
– –
-36,000
Closed -$1.22M
PTGX icon
47
Protagonist Therapeutics
PTGX
$8.51B
– –
-418,500
Closed -$5.03M
VCYT icon
48
Veracyte
VCYT
$3.58B
– –
-112,500
Closed -$2.7M
VIRX
49
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-11,429
Closed -$288K
MRTX
50
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-17,000
Closed -$1.32M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Acuta Capital Partners held 52 positions worth $404M, up 191% from $139M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Acuta Capital Partners deployed $92M of net new capital in Q4 2019, opening 21 new positions and adding to 12 existing holdings. Its largest new stake was Adverum Biotechnologies: 132,250 shares worth $15.2M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Arvinas, an estimated $6.16M trimmed.

  • Acuta Capital Partners's largest Q4 2019 buy was Adverum Biotechnologies: 132,250 shares worth $15.2M.
  • Acuta Capital Partners added most to Karyopharm Therapeutics in Q4 2019, an estimated $5.1M increase.
  • Acuta Capital Partners's biggest Q4 2019 reduction was Arvinas, cutting an estimated $6.16M.
  • Acuta Capital Partners fully exited CRISPR Therapeutics in Q4 2019, selling an estimated $5.49M.
  • Acuta Capital Partners's ten largest holdings make up 66% of its $404M portfolio in Q4 2019.
  • Acuta Capital Partners opened 21 new positions and closed 14 in Q4 2019.
  • Acuta Capital Partners's portfolio value rose 191% quarter-over-quarter to $404M.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.